454464-38-1

Basic information

• Product Name: 4-(4-Trifluoromethylphenyl)benzylchloride
• Synonyms: 4-(4-Trifluoromethylphenyl)benzylchloride
• CAS NO: 454464-38-1
• Molecular Formula: C₁₄H₁₀ClF₃
• Molecular Weight: 270.6774096
• Mol File: 454464-38-1.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(4-Trifluoromethylphenyl)benzylchloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-Trifluoromethylphenyl)benzylchloride(454464-38-1)
• EPA Substance Registry System: 4-(4-Trifluoromethylphenyl)benzylchloride(454464-38-1)

Safety Data

• Hazardous Substances Data: 454464-38-1(Hazardous Substances Data)

Upstream product

• 457889-46-2 (4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methanol 
• 128796-39-4 4-trifluoromethylphenylboronic acid 
• 589-17-3 p-bromobenzyl chloride 
• 5798-75-4 Ethyl 4-bromobenzoate 
• 647842-34-0 ethyl 4'-(trifluoromethyl)-[1,1'-biphenyl]-4-carboxylate 
• 1122-91-4 4-bromo-benzaldehyde 
• 873-75-6 4-bromobenzenemethanol 

Downstream Products

• 613239-54-6 [2-Methyl-4-(4'-trifluoromethyl-biphenyl-4-ylmethylsulfanyl)-phenoxy]-acetic Acid Methyl Ester 
• 613239-80-8 [5-Chloro-2-methyl-4-(4'-trifluoromethyl-biphenyl-4-ylmethylsulfanyl)-phenoxy]-acetic Acid Methyl Ester 
• 1030367-79-3 2-methyl-4-(((4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methyl)thio)phenol 
• 1030369-39-1 C₂₁H₁₇F₃OSe 
• 934753-43-2 methyl 4-[(4E)-3-(4-cyanobenzyl)-5-(2-{[4'-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)pent-4-en-1-yl]benzoate 
• 934737-89-0 [2-(4'-Trifluoromethylbiphenyl-4-yl-methoxy)phenyl]methanol 
• 934818-60-7 [5-Fluoro-2-(4'-trifluoromethylbiphenyl-4-ylmethoxy)phenyl]methanol 
• 1030369-40-4 C₂₇H₃₁F₃OSeSi 
• 1030369-41-5 C₃₄H₃₇F₃OSeSi 
• 1030369-43-7 C₃₄H₃₄F₆OSeSi 
• 1030369-47-1 C₂₈H₂₃F₃OSe 
• 1030369-48-2 C₃₂H₂₉F₃O₃Se 
• 1030369-50-6 C₃₄H₃₃F₃O₃Se 
• 1030369-51-7 C₃₅H₃₅F₃O₃Se 

Relevant articles and documents

RADIOLABELED DARAPLADIB AND ANALOGS THEREOF AND THEIR USE AS IMAGING COMPOUNDS

The present inventors have developed new radiolabeled Darapladib and analogs thereof which can be used for the specific detection of vulnerable atherosclerotic plaques by targeting lipoprotein-associated phospholipase A2 (Lp-PLA2) which is a biomarker of

Synthesis and evaluation of an orally available “Y”-shaped biaryl peroxisome proliferator-activated receptor δ agonist

In this study, we designed and synthesized several novel “Y”-shaped biaryl PPARδ agonists. Structure-activity relationship (SAR) studies demonstrated that compound 3a was the most active agonist with an EC50 of 2.6 nM. We also synthesized and evaluated enantiospecific R and S isomers of compound 3a to confirm that R isomer (EC50 = 0.7 nM) shows much more potent activity than S isomer (EC50 = 6.1 nM). Molecular docking studies between the PPAR ligand binding domain and enantiospecific R and S isomers of compound 3a were performed. In vitro absorption, distribution, metabolism, excretion, and toxicity (ADMET) and in vivo PK profiles show that compound 3a possesses superior drug-like properties including good bioavailability. Our overall results clearly demonstrate that this orally administrable PPARδ agonist 3a is a viable drug candidate for the treatment of various PPARδ-related disorders.

Tetrazole Derivatives and Their Use for the Treatment of Cardiovascular Diseases

The present application relates to novel tetrazole derivatives, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for producing medicaments for the treatment and/or prophylaxis of diseases, especial